Photo of Sue J. Goldie,  MD, MPH

Sue J. Goldie, MD, MPH

Harvard T.H. Chan School Of Public Health

Harvard T.H. Chan School Of Public Health
Phone: (617) 432-2010
Fax: (617) 432-0190


sue_goldie@harvard.edu

Sue J. Goldie, MD, MPH

Harvard T.H. Chan School Of Public Health

EDUCATIONAL TITLES

  • Roger Irving Lee Professor of Public Health, Health Policy and Management, Harvard T.H. Chan School Of Public Health
  • Professor, Global Health and Social Medicine, Harvard Medical School
  • Director, Center for Health Decision Science, Harvard T.H. Chan School Of Public Health
  • Director, Harvard Global Health Institute, Harvard University

DF/HCC PROGRAM AFFILIATION

Research Abstract

Sue J. Goldie, M.D., M.P.H. is a Professor of Health Decision Science, and the Director of the Program in Health Decision Science, in the Department of Health Policy and Management at the Harvard School of Public Health. She completed her postdoctoral clinical training in Internal Medicine at Yale University, and her MPH with a concentration in decision sciences at the Harvard School of Public Health. Her research focuses on applying the methods of decision science and cost-effectiveness analysis to applications which evaluate preventive, screening, and treatment interventions for sexually transmitted diseases (STDs) such as human immunodeficiency virus (HIV), human papillomavirus (HPV), hepatitis, and their sequelae (AIDS, cervical cancer and anal cancer, hepatocellular carcinoma). Target populations of particular interest include adolescents, women, and vulnerable or marginalized populations.

Publications

Powered by Harvard Catalyst
  • Yeh JM, Hur C, Ward Z, Schrag D, Goldie SJ. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut 2015. PubMed
  • Goldie SJ, Levin C, Mosqueira-Lov√≥n NR, Ortendahl J, Kim J, O'Shea M, Diaz Sanchez M, Mendoza Araujo MA. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. Rev. Panam. Salud Publica 2013; 32:426-34. PubMed
  • Price RA, Frank RG, Cleary PD, Goldie SJ. Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA tests. Med Care 2011; 49:132-8. PubMed
  • Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, Kim JJ. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 2010; 46:2973-85. PubMed
  • Levin CE, Sellors J, Shi JF, Ma L, Qiao YL, Ortendahl J, O'Shea MK, Goldie SJ. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer 2010; 127:1404-11. PubMed
  • Goldhaber-Fiebert JD, Stout NK, Goldie SJ. Empirically Evaluating Decision-Analytic Models. Value Health 2010; 13:667-74. PubMed
  • Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 2010; 116:2941-53. PubMed
  • Yeh JM, Nekhlyudov L, Goldie SJ, Mertens AC, Diller L. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med 2010; 152:409-17, W131-8. PubMed
  • Profit J, Lee D, Zupancic JA, Papile L, Gutierrez C, Goldie SJ, Gonzalez-Pier E, Salomon JA. Clinical benefits, costs, and cost-effectiveness of neonatal intensive care in Mexico. PLoS Med. 2010; 7:e1000379. PubMed
  • Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009; 151:538-45. PubMed
  • Yeh JM, Goldie SJ, Kuntz KM, Ezzati M. Effects of Helicobacter pylori infection and smoking on gastric cancer incidence in China: a population-level analysis of trends and projections. Cancer Causes Control 2009. PubMed
  • Wideroff L,Phillips KA,Randhawa G,Ambs A,Armstrong K,Bennett CL,Brown ML,Donaldson MS,Follen M,Goldie SJ,Hiatt RA,Khoury MJ,Lewis G,McLeod HL,Piper M,Powell I,Schrag D,Schulman KA,Scott J. A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics 2009; 12:233-44. PubMed
  • Yeh JM,Kuntz KM,Ezzati M,Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 2008; 124:157-66. PubMed
  • Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339:b3884. PubMed
  • Stout NK,Goldie SJ. Keeping the noise down: common random numbers for disease simulation modeling. Health Care Manag Sci 2008; 11:399-406. PubMed
  • Andersson KL,Salomon JA,Goldie SJ,Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008; 6:1418-24. PubMed
  • Goldie SJ,O'Shea M,Diaz M,Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008; 16:86-96. PubMed
  • Stout NK,Goldhaber-Fiebert JD,Ortendahl JD,Goldie SJ. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med 2008; 168:1881-9. PubMed
  • Kim JJ,Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821-32. PubMed
  • Goldie SJ,Diaz M,Constenla D,Alvis N,Andrus JK,Kim SY. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008; 26 Suppl 11:L59-72. PubMed
  • Garland SM,Cuzick J,Domingo EJ,Goldie SJ,Kim YT,Konno R,Parkin DM,Qiao YL,Sankaranarayanan R,Stern PL,Tay SK,Bosch FX. Recommendations for cervical cancer prevention in Asia Pacific. Vaccine 2008; 26 Suppl 12:M89-98. PubMed
  • Kim JJ,Brisson M,Edmunds WJ,Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008; 26 Suppl 10:K76-86. PubMed
  • Andrus JK,Lewis MJ,Goldie SJ,Garcia PJ,Winkler JL,Ruiz-Matus C,de Quadros CA. Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean. Vaccine 2008; 26 Suppl 11:L80-7. PubMed
  • Goldie SJ,Diaz M,Kim SY,Levin CE,Van Minh H,Kim JJ. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008; 26 Suppl 12:M17-29. PubMed
  • Munoz N,Franco EL,Herrero R,Andrus JK,de Quadros C,Goldie SJ,Bosch FX. Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008; 26 Suppl 11:L96-L107. PubMed
  • Goldie SJ,O'Shea M,Campos NG,Diaz M,Sweet S,Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008; 26:4080-93. PubMed
  • Kim JJ,Kobus KE,Diaz M,O'Shea M,Van Minh H,Goldie SJ. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 2008; 26:4015-24. PubMed
  • Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008; 198:500.e1-7. PubMed
  • Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. Journal of the National Cancer Institute 2008; 100:308-20. PubMed
  • Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches. Pharmacoeconomics 2008; 26:191-215. PubMed
  • Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007; 97:1322-8. PubMed
  • Kim SY, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ 2007; 85:833-42. PubMed
  • Kwon J, Carey M, Goldie S, Kim J. Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma. Obstet Gynecol 2007; 110:933; author reply 933-4. PubMed
  • Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, Goldie SJ, Hsu HE, Walensky RP, Dalban C, Sax PE, Girard PM, Freedberg KA. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med 2007; 8:439-50. PubMed
  • Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'shea MK, Xavier Bosch F, de Sanjose S, Franco EL. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007; 25:6257-70. PubMed
  • Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166:137-50. PubMed
  • Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Tour. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS 2007; 21:973-82. PubMed
  • Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med 2007; 356:1908-10. PubMed
  • Campos NG, Salomon JA, Servoss JC, Nunes DP, Samet JH, Freedberg KA, Goldie SJ. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007; 120:272-9. PubMed
  • Kwon JS, Carey MS, Goldie SJ, Kim JJ. Cost-effectiveness analysis of treatment strategies for Stage I and II endometrial cancer. J Obstet Gynaecol Can 2007; 29:131-9. PubMed
  • Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE, , Garcia F. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57:7-28. PubMed
  • Hu D, Bertozzi SM, Gakidou E, Sweet S, Goldie SJ. The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico. PLoS ONE 2007; 2:e750. PubMed
  • Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007; 5:11. PubMed
  • Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 43 Suppl 1:S113-8. PubMed
  • Kim JJ, Salomon JA, Weinstein MC, Goldie SJ. Packaging health services when resources are limited: the example of a cervical cancer screening visit. PLoS Med 2006; 3:e434. PubMed
  • Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Ce d'Ivoire. N Engl J Med 2006; 355:1141-53. PubMed
  • Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006; 24 Suppl 3:S155-63. PubMed
  • Goldie SJ, Kim JJ, Myers E. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine 2006; 24 Suppl 3:S164-70. PubMed
  • Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24 Suppl 3:S178-86. PubMed
  • Korves CT, Goldie SJ, Murray MB. Blood screening for west nile virus: the cost-effectiveness of a real-time, trigger-based strategy. Clin Infect Dis 2006; 43:490-3. PubMed
  • Goldhaber-Fiebert JD, Goldie SJ. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc 2006; 4:13. PubMed
  • Hu D, Hook EW, Goldie SJ. The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies. Sex Transm Dis 2006; 33:428-36. PubMed
  • Kimmel AD, Losina E, Freedberg KA, Goldie SJ. Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries. Bull World Health Organ 2006; 84:581-8. PubMed
  • Roux L, Kuntz KM, Donaldson C, Goldie SJ. Economic evaluation of weight loss interventions in overweight and obese women. Obesity (Silver Spring) 2006; 14:1093-106. PubMed
  • Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage GR, N'Dri-Yoman T, Walensky RP, Dakoury-Dogbo N, Goldie SJ, Messou E, Weinstein MC, Deuffic-Burban S, Salamon R, Freedberg KA. Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Ce d'Ivoire. S Afr Med J 2006; 96:526-9. PubMed
  • Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ,. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2006; 98:92-100. PubMed
Hide